Levetiracetam (Synonyms: UCB L059)

Name: Levetiracetam
Brand: MedChemExpress
SKU: HY-B0106
Rating: 4.5 (1 reviews)

Cat. No.: HY-B0106 Purity: 99.90%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.

For research use only. We do not sell to patients.

Levetiracetam Chemical Structure

CAS No. : 102767-28-2

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 87	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 87	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	USD 79	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 132	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 343	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Levetiracetam:

Etiracetam In-stock

1 Publications Citing Use of MCE Levetiracetam

•J Sep Sci. 2022 Apr 20. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All DNA Methyltransferase Isoform Specific Products:

View All Isoforms

DNA Methyltransferase DNMT1 DNMT3 MGMT

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

M2 mAChR^[1]

In Vitro

Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity^[1].
Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 μM) treatment^[1].
MGMT expression is downregulated in GCSCs treated with Levetiracetam (40 μg/mL)^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	GCSC neurospheres
Concentration:	40 μg/mL
Incubation Time:	48 hours
Result:	Slight antitumor effect exerted by the treatment with Temozolomide (250 µM) or Levetiracetam (40 μg/mL) alone was strongly enhanced when Temozolomide and Levetiracetam were added in combination.

Western Blot Analysis^[1]

Cell Line:	Glioblastoma multiforme stem-like cells (GSCs)
Concentration:	40 μg/mL
Incubation Time:	48 hours
Result:	A high level of MGMT expression in untreated GCSCs; this expression was slightly decreased after treatment with Temozolomide (250 µM) and Levetiracetam singularly but it was dramatically decreased after the combined treatment with Temozolomide and Levetiracetam.

In Vivo

Levetiracetam (10, 25, or 50 mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Long-Evans rats^[2]
Dosage:	10, 25, or 50 mg/kg
Administration:	Intraperitoneal injection 60 min before hypoxia.
Result:	Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25 mg/kg and at 50 mg/kg. Anticonvulsant activity was maximal at 50 mg/kg, at which HSs were reduced by 63.6%.

Molecular Weight

170.21

Formula

C₈H₁₄N₂O₂

CAS No.

102767-28-2

Unlabeled CAS

102767-28-2

Appearance

Solid

Color

White to off-white

SMILES

NC([C@@H](N(CCC1)C1=O)CC)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : ≥ 85 mg/mL (499.38 mM)

DMSO : ≥ 85 mg/mL (499.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.8751 mL	29.3755 mL	58.7510 mL
5 mM	1.1750 mL	5.8751 mL	11.7502 mL
10 mM	0.5875 mL	2.9375 mL	5.8751 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (587.51 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (280 KB) SDS (393 KB)

COA (251 KB) LCMS (261 KB)

Handling Instructions (2659 KB)

References

[1]. Bianca Maria Scicchitano, et al. Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell Int. 2018 Sep 10;18:136. [Content Brief]

[2]. Delia M Talos, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013 Jan;73(1):24-30. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	5.8751 mL	29.3755 mL	58.7510 mL	146.8774 mL
	5 mM	1.1750 mL	5.8751 mL	11.7502 mL	29.3755 mL
	10 mM	0.5875 mL	2.9375 mL	5.8751 mL	14.6877 mL
	15 mM	0.3917 mL	1.9584 mL	3.9167 mL	9.7918 mL
	20 mM	0.2938 mL	1.4688 mL	2.9375 mL	7.3439 mL
	25 mM	0.2350 mL	1.1750 mL	2.3500 mL	5.8751 mL
	30 mM	0.1958 mL	0.9792 mL	1.9584 mL	4.8959 mL
	40 mM	0.1469 mL	0.7344 mL	1.4688 mL	3.6719 mL
	50 mM	0.1175 mL	0.5875 mL	1.1750 mL	2.9375 mL
	60 mM	0.0979 mL	0.4896 mL	0.9792 mL	2.4480 mL
	80 mM	0.0734 mL	0.3672 mL	0.7344 mL	1.8360 mL
	100 mM	0.0588 mL	0.2938 mL	0.5875 mL	1.4688 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Levetiracetam Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Levetiracetam (Synonyms: UCB L059)

Customer Review

Other Forms of Levetiracetam:

Levetiracetam Related Antibodies

1 Publications Citing Use of MCE Levetiracetam

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All DNA Methyltransferase Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Levetiracetam Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Levetiracetam Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report